Indolinone compounds and uses thereof

Abstract

Indolinone derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indolinone derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.

What is claimed is: 
     
         1 . A compound having a structure of Formula (I): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof, wherein R 1 , R 2 , R 3 , and R 4  are independently selected from the group consisting of H, Cl, —CN and —CF 3 ; wherein A is selected from the group consisting of H and C 1-6  alkyl; wherein D is selected from the group consisting of —OH and —O(C 1-6  alkyl); wherein R 5  and R 6  are independently selected from the group consisting of H, F, and C 1-6  alkyl, or wherein R 5  and R 6  taken together form a substituted or unsubstituted cycloalkyl ring; wherein R 12  is independently selected from the group consisting of C 3-8  cycloalkyl and 
       
         
           
           
               
               
           
         
       
       wherein R 7 , R 8 , R 9 , R 10  and R 11  are independently selected from the group consisting of H, halogen, CN, CF 3 , C 1-6  alkyl, aryl, heteroaryl, —O(aryl), —O(heteroaryl), —CO 2 H, —CO 2 (C 1-6  alkyl), —NHSO 2 (C 1-6  alkyl), —NHSO 2 (aryl), —NHCONH(C 1-6  alkyl), —NHCON(C 1-6  alkyl) 2 , —N(C 1-6  alkyl)CONH 2 , —N(C 1-6  alkyl)CONH(C 1-6  alkyl), —N(C 1-6  alkyl)CON(C 1-6  alkyl) 2 , —SO 2 (C 1-6  alkyl), —SO 2 NH 2 , —SO 2 NH(C 1-6  alkyl), —SO 2 N(C 1-6  alkyl) 2 , C 3-8  cycloalkyl, and C 3-8  heterocyclo alkyl. 
     
     
         2 . The compound of  claim 1 , wherein R 9  is selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, and morpholinolyl. 
     
     
         3 . The compound of  claim 1 , wherein R 9  is selected from the group consisting of isopropyl and cyclopropyl. 
     
     
         4 . The compound of  claim 1 , having a structure of Formula (Ia): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof, wherein R 1 , R 2 , R 3 , and R 4  are independently selected from the group consisting of H and Cl; wherein R 7 , R 8 , R 10  and R 11  are independently selected from the group consisting of H and halogen; and wherein R 9  is independently selected from the group consisting C 3-8  cycloalkyl and C 3-8  heterocycloalkyl. 
     
     
         5 . The compound of  claim 1 , wherein R 1  and R 4  are Cl and R 2  and R 3  are H. 
     
     
         6 . The compound of  claim 1 , selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof. 
     
     
         7 . The compound of  claim 6 , selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof. 
     
     
         8 . The compound of  claim 1 , selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof. 
     
     
         9 . The compound of  claim 1 , selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof. 
     
     
         10 . The compound of  claim 1 , having the structure: 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof. 
     
     
         11 . The compound of  claim 1 , having the structure: 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a pharmaceutically acceptable salt, ester, or solvate thereof. 
     
     
         12 . A pharmaceutical composition comprising the compound of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         13 . A method for inhibiting proliferation of a cell, wherein the cell overexpresses an ETS gene or comprises an ETS fusion gene, comprising contacting the cell with an effective amount of the compound of  claim 1 . 
     
     
         14 . The method of  claim 13 , wherein the ETS gene or the ETS fusion gene is selected from the group consisting of FLI1, ERG, ETV1, and ETV4. 
     
     
         15 . The method of  claim 13 , wherein the cell is a cancer cell, wherein the cancer is selected from the group consisting of Ewing's sarcoma, prostate cancer, glioblastoma, acute myeloid leukemia, breast cancer, head cancer, neck cancer, melanoma, non-small cell lung cancer, ovarian cancer, and uterine cancer. 
     
     
         16 . The method of  claim 13 , wherein the cell is mammalian. 
     
     
         17 . A method of killing or inhibiting the growth of a neoplastic cell, comprising contacting the cell with an effective amount of the compound of  claim 1 . 
     
     
         18 . The method of  claim 17 , wherein the cell is a cancer cell, wherein the cancer is selected from the group consisting of Ewing's sarcoma, prostate cancer, glioblastoma, acute myeloid leukemia, breast cancer, head cancer, neck cancer, melanoma, non-small cell lung cancer, ovarian cancer, and uterine cancer. 
     
     
         19 . The method of  claim 17 , wherein the cell is mammalian.